KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Restructuring (2016 - 2017)

Vertex Pharmaceuticals (VRTX) has 9 years of Cash from Restructuring data on record, last reported at -$2.1 million in Q4 2017.

  • For Q4 2017, Cash from Restructuring fell 392.97% year-over-year to -$2.1 million; the TTM value through Dec 2017 reached -$6.0 million, up 19.38%, while the annual FY2017 figure was -$6.0 million, 19.38% up from the prior year.
  • Cash from Restructuring reached -$2.1 million in Q4 2017 per VRTX's latest filing, up from -$2.8 million in the prior quarter.
  • Across five years, Cash from Restructuring topped out at $36.6 million in Q3 2014 and bottomed at -$24.4 million in Q1 2015.
  • Average Cash from Restructuring over 5 years is -$1.1 million, with a median of -$1.6 million recorded in 2015.
  • The widest YoY moves for Cash from Restructuring: up 796.18% in 2014, down 1099.75% in 2014.
  • A 5-year view of Cash from Restructuring shows it stood at $2.2 million in 2013, then plummeted by 540.05% to -$9.7 million in 2014, then soared by 74.96% to -$2.4 million in 2015, then soared by 129.7% to $725000.0 in 2016, then plummeted by 392.97% to -$2.1 million in 2017.
  • Per Business Quant database, its latest 3 readings for Cash from Restructuring were -$2.1 million in Q4 2017, -$2.8 million in Q3 2017, and -$1.4 million in Q2 2017.